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Abstract
Introduction For drugs eliminated by glomerular filtration (GF), clearance (CL) is determined by GF rate (GFR) and the 
unbound fraction of the drug. When predicting CL of GF-eliminated drugs in children, instead of physiologically based phar-
macokinetic (PBPK) methods that consider changes in both GFR and protein binding, empiric bodyweight-based methods 
are often used. In this article, we explore the predictive value of scaling using a GFR function, and compare the results with 
linear and allometric scaling methods for drugs with different protein-binding properties.
Methods First, different GFR maturation functions were compared to identify the GFR function that would yield the most 
accurate GFR predictions across the pediatric age range compared with published pediatric inulin/mannitol CL values. 
Subsequently, the accuracy of pediatric CL scaling using this GFR maturation function was assessed and compared with 
PBPK CL predictions for hypothetical drugs binding, to varying extents, to serum albumin or α-acid glycoprotein across the 
pediatric age range. Additionally, empiric bodyweight-based methods were assessed.
Results The published GFR maturation functions yielded comparable maturation profiles, with the function reported by 
Salem et al. leading to the most accurate predictions. On the basis of this function, GFR-based scaling yields reasonably 
accurate (percentage prediction error ≤ 50%) pediatric CL values for all drugs, except for some drugs highly bound to AGP 
in neonates. Overall, this method was more accurate than linear or 0.75 allometric bodyweight-based scaling.
Conclusion When scaling CL and dose by GFR function, maturational changes in plasma protein concentrations impact GF 
minimally, making this method a superior alternative to empiric bodyweight-based scaling.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-020-00890 -2) contains 
supplementary material, which is available to authorized users.
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Key Points 
A maturation function for glomerular filtration is pre-
ferred for scaling clearance (CL) and doses from adults 
to the pediatric population over empiric bodyweight-
based methods.
Maturation in the expression of drug binding plasma pro-
teins and associated changes in unbound drug fractions 
has limited influence on pediatric CL and dose scaling, 
except for α-acid glycoprotein-bound drugs in neonates.
Our findings are relevant for defining (first-in-child) 
doses in clinical studies, particularly for drugs for which 
differences in dose requirements between adults and 
children can be attributed entirely to differences in phar-
macokinetics.
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1 Introduction
Clearance (CL) is the driving parameter for dosing as it 
determines steady-state and trough concentrations. For 
children, precise scaling of CL without bias across the 
pediatric age range is paramount to reach both an effective 
and safe (starting) dose. This is of relevance for defining 
(first-in-child) doses in clinical studies, particularly for 
drugs for which differences in dose requirements between 
adults and children can be attributed entirely to differences 
in pharmacokinetics (PK) and/or for which target concen-
trations in children are known [1].
CL of drugs eliminated through glomerular filtration 
(GF) is dependent on the GF rate (GFR) and plasma pro-
tein binding. GFR maturation across the pediatric popu-
lation has been described by different functions based 
on data from CL of either endogenous (e.g. creatinine, 
cystatin C) or exogenous (e.g. inulin, iohexol, aminogly-
cosides) compounds, used as markers for GFR function 
[2–7]. With respect to plasma protein binding, changes in 
the unbound drug fraction (fu) with age need to be taken 
into account when predicting pediatric CL via GF, as only 
the drug fraction that is not bound to plasma proteins can 
be eliminated through GF. The unbound fraction across 
age is dependent on the protein the drug binds to (i.e. 
human serum albumin or α-acid glycoprotein [AGP]) and 
the changes in the concentrations of these proteins with 
age [8]. As physiologically-based PK (PBPK) models 
include drug properties (i.e. fu) and physiological dif-
ferences between adults and children (i.e. maturation of 
plasma protein concentrations and GFR), these models 
are considered the ‘gold standard’ for pediatric CL pre-
dictions [9].
However, the application of PBPK approaches is con-
strained by the availability of drug-specific data, skilled 
personnel, and resources needed to access and use differ-
ent modeling platforms. Therefore, empirical bodyweight-
based scaling methods such as linear scaling or allometric 
scaling with a fixed exponent of 0.75 are still often used 
to derive pediatric CL from adult CL values. However, 
empirical scaling methods disregard information about 
maturation of both GFR and protein binding. Previous 
work has shown that these approaches are inaccurate for 
certain pediatric age groups for drugs cleared by GF [10, 
11], suggesting that more mechanistic information may be 
needed for accurate scaling. For this, it has been proposed 
to adjust the allometric scaling with a maturation function 
for GFR, especially in the very young [12]. In this article, 
we assess the accuracy of scaling based on GFR matura-
tion, without taking into account maturational changes in 
fu. We compare this approach with two relatively straight-
forward scaling methods based on bodyweight alone, since 
these methods are still often used and are perhaps even 
preferred because of their ease.
To this end, we first identified the GFR maturation func-
tion that yields the most accurate GFR predictions across the 
pediatric age range. Subsequently, we assessed the accuracy 
of pediatric CL and dose scaling obtained with the GFR 
maturation function compared with PBPK predictions for 
hypothetical drugs binding, to varying extents, to human 
serum albumin (HSA) or AGP across the pediatric age 
range. Additionally, the results are compared with those of 
the two empiric bodyweight-based methods, i.e. linear and 
allometric scaling with a fixed exponent of 0.75.
2  Methods
2.1  Establishing the Most Accurate Pediatric 
Glomerular Filtration Rate (GFR) Maturation 
Function
Functions that quantify GFR maturation throughout the pedi-
atric age range for children with normal renal functionality, 
and that only used demographic characteristics as input, were 
collected from the literature by searching the PUBMED data-
base using the search term “glomerular filtration maturation 
children human”, or from Simcyp v18 resources. Seven [7, 
13–17] functions were identified, of which six [13–17] were 
developed based on exogenous markers for GFR (i.e. inulin, 
-Cr-EDTA, mannitol, iohexol) and one [7] was derived from 
CL values of antibiotics that are predominantly eliminated 
through GF. To visually compare the different GFR matu-
ration profiles, age-appropriate body surface area (BSA), 
height, and weight values were derived from the National 
Health and Nutrition Examination Survey (NHANES) data-
base [18] and used for GFR predictions with each of the 
seven functions.
In this analysis, inulin and mannitol CL values were con-
sidered the ‘gold standard’ for GF function [19, 20], and 
hence were used to select the most accurate pediatric GFR 
maturation function. GFR predictions with each of the seven 
maturation functions were compared with the inulin [3–6] 
and mannitol [2] CL values published for children, for whom 
the necessary demographic characteristics were reported. 
Individual data were either digitized using WebPlotDigi-
tizer (https ://apps.autom eris.io/wpd/) or extracted directly 
from the publications. When inulin and mannitol CL values 
were reported relative to the standard adult BSA (i.e. nor-
malized by 1.73 m2), they were converted to absolute values. 
When gestational age was missing, a gestational period of 
38 weeks was imputed. Missing BSA values were calculated 
based on age and bodyweight using the Haycock et al. [21] 
and Dubois et al. [22] formulas for children under and over 
15 kg, respectively.
GFR-Based Scaling of Pediatric Clearance and Doses
For the seven GFR maturation functions, the demo-
graphic characteristics corresponding to the individuals 
for whom inulin [3, 4, 6] and mannitol [2] CL values were 
available were used as input, and the resulting predic-
tions were compared with the reported measurements. For 
this, a percentage prediction error (%PEGFR) between the 
predicted GFR with each function and the inulin [3, 4, 6] 
and mannitol [2] CL values was calculated according to 
Eq. (1). In addition, the root mean square percentage error 
(%RMSPEGFR) was calculated using Eq. (2), for the entire 
pediatric population as well as selected age groups, to show 
the stratified accuracy of the GFR functions for preterm 
neonates, term neonates on the first day, newborns aged 
between 1 day and 1 month, and children aged between 
1 and 6 months, 6 months and 1 year, 1 and 5 years, and 
between 5 and 15 years. In Eqs. (1) and (2), the predicted 
GFR are values obtained with each of the published GFR 
maturation functions, and observed  CLinulin/mannitol are the 
published values for inulin or mannitol CL.
(1)
%PEGFR =
predicted GFR − observed CLinulin/manitol
observed CLinulin/manitol
× 100
2.2  Evaluation of Pediatric Clearance (CL) Scaling
To evaluate the accuracy of pediatric CL scaling using the 
selected GFR function or empiric functions, a ‘true’ CL value 
is needed as reference. As PBPK-based approaches are consid-
ered the ‘gold standard’ for pediatric CL predictions, the renal 
PBPK model in Eq. (3) was used to derive ‘true’ CL values. 
‘True’ CL of hypothetical drugs was predicted for typical pedi-
atric individuals at ages 1 day, 1, 3, 6 and 9 months, 2, 5, 10, 
and 15 years, and a 35-year-old typical adult.
In Eq. (3), pediatric GFR values were obtained using the 
best maturation function selected above. Demographic values 
needed to predict pediatric GFR values with the best GFR 
maturation function were derived from the NHANES database 
[18] and the International Commission on Radiological Pro-
tection (ICRP) annals [24] for children and adults, respectively.
For fu in Eq. (3), a total of 20 hypothetical drugs were evalu-
ated. For these drugs, fu values in adults (fu,adult) of 0.1, 0.2, 0.3, 
0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 were used and each drug was 
assumed to exclusively bind to either HSA or AGP. Pediatric 
fu values (fu,ped) at each pediatric age were obtained based on 
(3)�true� CL = GFR × fu
(2)%RMSPEGFR =
√√√√1
n
×
n∑
i=1
(
predicted GFR − observed CLinulin/manitol
observed CLinulin/manitol
)2
the ratios between relevant binding protein concentrations and 
the fu,adult, according to Eq. (4) [8]:
where [P] represents the plasma concentration of the rel-
evant binding protein (i.e. HSA or AGP).
Equations (5) and (6) [15] were used to calculate the plasma 
concentrations ([P]) of HSA and AGP, respectively, for typical 
children of different ages, with age expressed in days. Visual 
representations of the maturation profiles of the plasma pro-
teins, as well as of the resulting fu,ped values, are presented in 
electronic supplementary Fig. S1.
where [HSA(g/L)] and [AGP(g/L)] represent the plasma pro-
tein concentrations, and Age is the age of the typical child 
expressed in days [15].
(4)fu,ped =
1
1 +
[P]ped×(1−fu,adult)
[P]adult×fu,adult
(5)
[
HSA(g∕L)
]
= 1.1287 × ln (Age) + 33.746
(6)
[
AGP(g∕L)
]
=
0.887 × Age0.38
8.890.38 + Age0.38
As the predictions do not include variability or uncer-
tainty in any of the terms, only point estimates of %PEGFR 
and %RMSPEGFR are obtained. To compensate for this, 
rather than applying the twofold rule that is commonly 
used in assessing the accuracy of PBPK model prediction, 
we designated values within ± 30% to be ‘accurate pre-
dictions’, values outside the ± 50% interval to be ‘inaccu-
rate’, and values in between to be ‘reasonably accurate’ for 
%PEGFR. For %RMSPEGFR, values within 0–30% indicate 
‘accurate predictions’, values > 50% indicate ‘inaccurate 
predictions’, and values within 30–50% are ‘reasonably 
accurate’. The GFR maturation function that would lead to 
the narrowest range in %PEGFR predictions and the small-
est %RMSPEGFR overall and per age group was selected 
and used in the PBPK-based approach, as well as in the 
evaluation of pediatric CL scaling.
The results here do not include findings for preterm 
neonates, as only four [7, 13, 15] of the seven GFR matu-
ration functions were also developed for preterm neonates. 
Inulin and mannitol data collected from preterm neonates 
[3, 5, 23] were analyzed separately, together with these 
four functions, and the results can be found in the elec-
tronic supplementary material (ESM).
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2.3  GFR‑based Scaling of CL
For GFR-based scaling of CL from adults to children of 
different ages Eq. (7) is used. Here ‘true’ adult CL val-
ues of the drug, i.e.  GFRadult multiplied by fu,adult (for 20 
hypothetical drugs, see Eq. 3), were scaled by the ratio 
between  GFRped and  GFRadult, with  GFRped calculated 
according to the selected function (see results, Salem et al. 
[17], Eq. 12). Note that fu, adult is included for obtaining the 
‘true’ adult CL values; however, changes in fu with age are 
not included when applying GFR-based scaling (Eq. 7).
2.4  Empiric and Linear Body‑Weight Based Scaling 
Methods
For comparative purposes, the accuracy of GFR-based 
scaling was evaluated together with linear bodyweight-
based scaling (Eq.  8) and bodyweight-based allomet-
ric scaling with a fixed exponent of 0.75 (Eq. 9), which 
are two commonly used empirical pediatric CL scaling 
methods.
2.5  Comparison of Different Scaling Methods
The accuracy of CL obtained with GFR-based, linear, 
and allometric scaling with a fixed exponent of 0.75 was 
assessed by calculating the %PECL as compared with the 
‘true’  Clped, according to Eq. (10). Note that in ‘true’  CLped 
(Eq. 3) the changes in fu with age are considered, accord-
ing to Eqs. (4)–(6).
2.6  Assessment of Pediatric Dose Scaling
As CL scaling is commonly used as the basis for dose scal-
ing, the implications of the different CL scaling methods 
on the accuracy of the dose adjustments derived from them 
(7)GFR scaled CLped =� true� CLadult ×
(
GFRped
GFRadult
)
(8)Linear scaled CLped = �true� CLadult ×
(
WTped
WTadult
)
(9)
Allometric scaled CLped =
�true�CLadult ×
(
WTped
WTadult
)0.75
(10)%PECL =
scaled CLped −
� true�CLped
�true�CLped
× 100
were also assessed. For each of the 20 hypothetical drugs 
for which ‘true’ adult CL values (Eq. 3) were calculated, 
Eq. (11) was used to derive the pediatric dose.
where  CLped refers to CL values obtained with either of the 
three simplified scaling methods (GFR-based scaling, linear 
scaling, or allometric scaling with a fixed exponent of 0.75) 
according to Eqs. (7), (8), and (9), respectively. This method 
assumes steady-state conditions (i.e. drug exposure is only 
dependent on dose and CL) and that the same drug target 
exposure (i.e. AUC) is applicable in children and adults. As 
relative dose adjustments were assessed, the adult dose was 
expressed as 1.
The ‘true’ reference doses were obtained by replacing the 
 CLped value in Eq. (11) with the ‘true’  CLped value (Eq. 3). 
The accuracy of the scaled doses was assessed by calculating 
the %PEdose according to Eq. (10).
3  Results
3.1  Establishing the Most Accurate Pediatric GFR 
Maturation Function
Figure 1 shows the seven published GFR maturation profiles 
[7, 13–17]. All profiles are comparable with the steepest 
maturation occurring in the first 2 years of life and plateau 
values being reached beyond the age of 15 years.
Figure 2 depicts the %PEGFR between GFR predictions 
according to the seven different functions versus the inu-
lin [3, 4, 6] or mannitol [2] CL measurements. In addition, 
Table 1 presents the %RMSPEGFR and the range in %PEGFR 
per age group, as well as for the entire pediatric age range. 
The results show that all functions tend towards overpre-
diction of GFR in the very young. In newborns, interindi-
vidual variability is higher than in older children, which 
yields the largest spread in %PEGFR for all GFR functions, 
with values ranging between − 112 and 484%. Furthermore, 
%RMSPEGFR in newborns can reach values of 158% com-
pared with values below 50% in older children. For all func-
tions, the %PEGFR range becomes narrower with increasing 
age, and, above 5 years, most functions lead to accurate pre-
dictions (%PEGFR within ± 30%). The function reported by 
Salem et al. [17] had the best predictive performance per age 
group and across all pediatric ages. These GFR predictions 
were similar to those obtained using the function reported by 
Rhodin et al. [14], as indicated by the  RMSPEGFR% values 
and %PEGFR ranges for the entire population, as well as for 
the different age groups. Results for preterm neonates are 
(11)doseped = doseadult ×
(
CLped
�true�CLadult
)
× 100
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presented in the ESM (electronic supplementary Fig. S2 and 
Table S1). 
From these results, the GFR maturation function pub-
lished by Salem et al. [17] (Eq. 12) was selected and used in 
the renal PBPK model (Eq. 3) to determine the ‘true’ renal 
CL of the 20 hypothetical drugs for the typical adult and 
the typical pediatric individuals. These GFR values are also 
used in Eq. (7) to calculate GFR-based scaled CL values 
across the pediatric range.
where PMA is defined as postmenstrual age in weeks, and 
 TM50 is defined as the PMA at which GFR reaches half the 
adult levels.
3.2  Evaluation of Pediatric CL Scaling
Figure 3 shows the %PECL for GFR-based scaling and for 
the two empirical bodyweight-based scaling methods, none 
of which take into account changes in plasma protein con-
centrations. The figure illustrates how scaling accuracy of 
CL with each of the three methods is impacted by fu (color 
intensifies with increased fu) and plasma protein concentra-
tions at every investigated age. Overall, GFR-based scaling 
is more accurate than the two empirical bodyweight-based 
methods, leading to %PECL values within ± 50% through-
out the pediatric age range, except for children aged 1 day 
for drugs with high binding to AGP (fu adult < 0.3). Body-
weight-based allometric scaling with a fixed exponent of 
0.75 is mostly inaccurate for individuals aged < 3 months. 
(12)
GFRml/min = 112 ×
(
Weight (kg)
70
)0.63
×
PMA3.3
PMA3.3 + TM3.3
50
GFR-based scaling and linear scaling outperform allometric 
scaling for these subjects. For children between 6 months 
and 15 years of age, linear scaling is reasonably accurate, 
albeit with a trend in %PECL values, indicating systematic 
bias towards underprediction. In this age range, similar, yet 
less strong, trends are seen for allometric scaling with a fixed 
exponent of 0.75, while GFR-based scaling is generally the 
most accurate of the three (Fig. 3).
3.3  Assessment of Pediatric Dose Scaling
Figure 4 and Table 2 show pediatric doses (expressed as a 
percentage of the adult dose) obtained using ‘true’ CL values 
versus those obtained using CL values upon scaling by the 
three simplified methods in typical patients for 20 hypotheti-
cal drugs differing in fu in adults and binding to either HSA 
or AGP. Both the figure and table show that the ‘true’ doses 
predicted based on ‘true’ pediatric CL values are depend-
ent on fu, whereas the scaled doses derived from CL values 
scaled using the three different simplified methods (i.e. GFR 
scaling, linear scaling, and allometric scaling) are not. Over-
all, the results show that doses obtained with GFR-based 
scaling are lower than the ‘true’ reference doses for drugs 
highly bound (i.e. fu = 0.1) to HSA or AGP (up to 20–60%, 
respectively). For drugs with low protein binding (i.e. 
fu = 0.9), the differences between the ‘true’ reference dose 
and GFR-based scaled doses are small throughout the pedi-
atric age range (< 5% difference). Using linear bodyweight-
based scaling, doses are also lower than the ‘true’ reference 
doses for children aged between 6 months and 10 years 
(up to 25.5–49% lower). For younger children, the differ-
ence between doses becomes smaller (< 30% difference). 
Doses obtained using bodyweight-based allometric scaling 
Fig. 1  Pediatric GFR according to published GFR maturation functions [7, 13–17] throughout the pediatric age range. a Semi-logarithmic scale; 
b double logarithmic scale. GFR glomerular filtration rate
 S. Cristea et al.
with a fixed exponent of 0.75 are generally higher than the 
‘true’ reference doses for children younger than 6 months of 
age. For this method, the highest difference of > 150% was 
obtained for drugs with high fraction unbound in children 
younger than 1 month (Fig. 4, Table 2). 
4  Discussion
This study aimed to identify the GFR maturation func-
tion that yields the most accurate GFR predictions across 
the entire pediatric age range, and to subsequently assess 
what the accuracy of GFR-based scaling of CL and dose 
is compared with the “gold standard” (i.e. PBPK-based 
predictions) and with two commonly used empiric body-
weight-based scaling methods. By comparing scaled CL 
values with PBPK CL predictions, we studied the influ-
ence of the maturation of plasma protein concentrations 
on CL and dose scaling, and showed at what ages this 
maturation is of relevance for each scaling method. The 
assessed scaling methods are typically used to guide pedi-
atric dosing when little or no information is available on a 
drug in this population. As such, this work identifies drug 
properties (i.e. fu) and patient characteristics (i.e. age) for 
Fig. 2  %PEGFR between individual predictions, based on the seven 
published GFR maturation functions [7, 13–17] and individual litera-
ture data on inulin [3, 4, 6] and mannitol [2] clearance values versus 
age. The results for each published GFR maturation function are dis-
played in separate panels (a–g). The dashed line is the null-line, and 
solid lines represent the %PEGFR of ± 50% range that was considered 
to indicate reasonably accurate scaling. %PEGFR percentage predic-
tion error, GFR glomerular filtration rate, HSA human serum albu-
min, AGP α-acid glycoprotein
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which bodyweight-based scaling methods suffice and when 
more mechanistic information is necessary by means of 
either GFR-based scaling or PBPK for accurate CL and 
dose scaling. Our findings provide guidance for (first-in-
child) clinical studies on what scaling method to use when 
deriving pediatric doses from adult doses of small mol-
ecule drugs that are mainly eliminated by GF.
The published GFR maturation functions we evaluated 
were found to have comparable profiles, while the functions 
published by Salem et al. [17] and Rhodin et al. [14] had 
Fig. 3  %PECL between ‘true’ CL values and CL values obtained 
using three different simplified scaling methods in typical pediatric 
patients for 20 hypothetical drugs differing in unbound drug frac-
tion in adults and binding to either HSA (left panel) or AGP (right 
panel). Green dots indicate GFR-based scaling, orange dots indicate 
linear bodyweight-based scaling, and red dots indicate bodyweight-
based scaling with a fixed allometric exponent of 0.75. Colors 
intensify with increasing fu. The grey solid line is the null-line, and 
black dashed lines and black dotted lines represent the %PECL range 
of ± 30% and ± 50%, respectively, which indicate accurate and rea-
sonably accurate scaling, respectively. %PECL percentage prediction 
error, CL clearance, GFR glomerular filtration rate, fu unbound drug 
fraction
Fig. 4  Pediatric doses (a percentage of the adult dose) obtained with 
‘true’ CL values (black dots) and CL values obtained with three dif-
ferent simplified scaling methods (lines) in typical pediatric patients 
for 20 hypothetical drugs differing in fu in adults and binding to 
either HSA (left panel) or AGP (right panel). Green line indicates 
dose values obtained with GFR-based scaling, orange line indicates 
dose values obtained with linear bodyweight-based scaling, and red 
line indicates dose values obtained with bodyweight-based scaling 
with a fixed allometric exponent of 0.75. The black dots indicate dose 
values obtained with ‘true’ CL. Color intensifies with increasing fu. 
CL clearance, fu unbound drug fraction, HSA human serum albumin, 
AGP α-acid glycoprotein, GFR glomerular filtration rate
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similar accuracy in predicting inulin [3, 4, 6] and manni-
tol [2] CL measures, with the function reported by Salem 
et al. [17] being slightly more accurate overall. This function 
(Eq. 12) was used in PBPK-based predictions of ‘true’ pedi-
atric CL values (Eq. 3) and was directly used for simplified 
GFR-based scaling (Eq. 7).
Drug CL by GF depends on GFR and plasma protein 
binding, which are taken into account by PBPK modeling 
approaches. However, the extent of protein binding and the 
proteins the drugs bind to may not always be known, espe-
cially for the pediatric population. The simplified scaling 
functions, which include GFR-based scaling (Eq. 7), body-
weight-based linear scaling (Eq. 8), and bodyweight-based 
allometric scaling with a fixed exponent of 0.75 (Eq. 9), 
typically do not take into account changes in plasma pro-
tein binding with age. The difference between GFR-based 
scaled pediatric CL values and ‘true’ pediatric CL values 
reflects the impact of ignoring maturation in plasma protein 
concentrations on CL scaling. The current analysis showed 
that with GFR-based scaling, this impact can be disregarded 
throughout the entire pediatric age range, except in neonates 
for a few drugs highly bound to AGP (Fig. 3). Prediction 
errors in scaled CL values are largest in neonates, especially 
for drugs that bind to AGP, possibly due to the steep matura-
tion of AGP plasma concentrations in early life (electronic 
supplementary Fig. S1). GFR-based scaling leads to under-
prediction of CL in neonates and in drug doses, compared 
with ‘true’ CL and ‘true’ reference doses, which will result 
in not only a reduced risk of developing toxic effects but 
also an increased risk of treatment failure. Bodyweight-
based allometric scaling with a fixed exponent of 0.75 tends 
to overpredict CL in children younger than 6 months, even 
though for drugs with a low fu, maturational changes in the 
expression of drug binding plasma proteins can still partially 
correct this bias. Bodyweight-based linear scaling leads to 
reasonably accurate CL predictions in this young population. 
After the age of 6 months, the influence of plasma protein 
binding on CL scaling decreases, as shown by a smaller 
deviation of GFR-based scaled CL from PBPK-based CL 
predictions. In this age range, reasonably accurate CL 
predictions are obtained using bodyweight-based scaling, 
irrespective of whether the exponent is 1 (linear scaling), 
0.75 (allometric scaling), or 0.62 (GFR function reported 
by Salem et al. [17]). As scaled CL values drive the scaled 
dose values, the same patterns are observed for this variable.
The CL predictions of selected drugs (> 80% renal 
elimination) in neonates and children, using the GFR 
maturation function reported by Rhodin et al. [14], has 
recently been described [25]. Our results are in line with 
these published findings, with the added advantage that 
our analysis captures the entire hypothetical parameter 
space regarding the relevant drug-specific parameters (i.e. 
extent and type of plasma protein binding). As such, the 
presented analysis covers drugs that are currently in clini-
cal use and other small molecule drugs that are still to be 
developed. Therefore, this framework can be used to make 
Table 2  Pediatric doses presented as % of adult dose for drugs eliminated through GFR with varying fu values
The ‘true’ doses predicted based on ‘true’ pediatric CL values are dependent on fu whereas the scaled doses derived from CL values scaled with 
the three different scaling methods (i.e. GFR scaling, linear scaling and allometric scaling) are not
AGP α-acid glycoprotein, CL clearance, fu unbound drug fraction, GFR glomerular filtration rate, HSA human serum albumin, ICRP Interna-
tional Commission on Radiological Protection, NHANES National Health and Nutritional Examination Survey
a Weights derived from (1) the NHANES database [18] for children, and (2) the ICRP annals [24] for adults
b GFR values were obtained with Salem et al. [17]
Demographic characteristics of typical 
individuals
‘True’ dose (% of adult dose) obtained based on ‘true’ 
CL
Scaled dose (% of adult dose) obtained 
using three CL scaling methods
Age Weighta (kg) GFRb (mL/min) Drugs binding to HSA Drugs binding to AGP GFR scaling (%) Linear 
scaling 
(%)
Allometric 
scaling (%)
fu = 0.1 (%) fu = 0.9 (%) fu = 0.1 (%) fu = 0.9 (%)
1 day 3.4 4.3 5 4.1 10.1 4.2 4 5.2 11
1 month 4.3 6.2 6.6 5.8 8.3 5.9 5.7 6.5 13
3 months 5.8 10.7 11.1 10 12.7 10.1 9.9 8.6 16
6 months 7.5 17.6 17.9 16.4 19.6 16.5 16.2 11.4 20
9 months 8.9 23.2 23.5 21.6 25.1 21.8 21.4 13.4 22
1 year 9.9 27.4 27.5 25.5 29.1 25.6 25.3 14.9 24
2 years 12.3 35.9 35.4 33.3 36.5 33.4 33.1 18.6 28
5 years 18.2 47.7 46 44.2 46.6 44.3 44 27.4 38
10 years 32.5 68.9 65.4 63.8 65.6 63.8 63.6 48.9 58
15 years 54.2 95.3 89.7 88.1 89.7 88.1 87.9 81.6 86
Adult 66.5 108.4 100 100 100 100 100 100 100
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a priori assessments on the accuracy of the pediatric CL 
and dose-scaling methods for new drugs.
The current results are also in line with previous find-
ings from our group comparing ‘true’ PBPK-based CL 
predictions with CL values scaled by both empirical meth-
ods; however, small differences in numerical results are 
present. These differences are caused by two different GFR 
maturation functions being used in the PBPK model for 
predictions of the ‘true’ CL values. For the current analy-
sis, we used the function published by Salem et al. [17], 
which we found to be most accurate, whereas, in the previ-
ous analyses, the function by Johnson et al. [15] was used.
The conclusions from our analysis are based on typi-
cal individuals and do not take interindividual variability 
into account. For preterm and term neonates younger than 
1 month, high variability in the inulin [3, 4, 6] and manni-
tol [2] CL data is observed, which poses a challenge when 
scaling CL and doses to this age range. This suggests that 
variables other than the demographics used in GFR matu-
ration functions are predictive of GFR-based CL. For this 
special population, dosing recommendations that rely on 
empiric PK models of the same drug, even in slightly older 
children, or of a similar drug that is mainly eliminated 
through GF in the same population, may therefore offer a 
better alternative [26, 27].
We emphasize that all published GFR maturation func-
tions included in our analysis describe GFR maturation in 
pediatric individuals with normal renal function. These 
functions should therefore not be used for CL or dose 
scaling for pediatric patients with renal deficiencies. To 
account for renal impairment, functions that require a bio-
marker for renal function (e.g. creatinine, cystatin C, etc.) 
as input are more reliable and suitable to predict GFR. 
These functions can be implemented in the renal PBPK 
model in Eq. (3) and can also be used for GFR-based scal-
ing. The impact of ignoring plasma protein binding in 
these scenarios may not be the same as observed in the 
current analysis, as plasma protein binding may also be 
altered in patients with renal deficiencies.
5  Conclusion
The maturation function reported by Salem et al. [17] 
(Eq. 12) describes GFR most accurately throughout the 
pediatric age range compared with data on inulin and 
mannitol CL. GFR-based CL and dose scaling for drugs 
eliminated through GFR yields reasonably accurate pedi-
atric CL and dose values, despite ignoring the influence of 
maturational changes in protein binding, except for drugs 
highly bound to AGP in neonates.
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